Domača stranLT3 • FRA
add
AxoGen, Inc Common Stock
Prejšnji trg. dan.
10,30 €
Dnevni razpon
10,30 € - 10,60 €
Letni razpon
5,20 € - 19,20 €
Tržna kapitalizacija
538,79 mio. USD
Povprečni obseg
7,00
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
NASDAQ
Borzne novice
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | mar. 2025info | Sprememba L/L |
|---|---|---|
Prihodek | 48,56 mio. | 17,36 % |
Stroški poslovanja | 36,59 mio. | −1,58 % |
Čisti dohodek | −3,83 mio. | 42,22 % |
Čista dobičkovnost prihodkov | −7,90 | 50,75 % |
Earnings per share | −0,02 | 66,67 % |
EBITDA | 134,00 tis. | 104,50 % |
Efektivna davčna stopnja | — | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | mar. 2025info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 22,07 mio. | 25,15 % |
Skupna sredstva | 196,16 mio. | 5,17 % |
Skupne obveznosti | 90,80 mio. | −2,74 % |
Celoten lastniški kapital | 105,36 mio. | — |
Shares outstanding | 45,54 mio. | — |
Razmerje P/B | 4,44 | — |
Donosnost sredstev | −2,08 % | — |
Donosnost kapitala | −2,36 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | mar. 2025info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −3,83 mio. | 42,22 % |
Denar iz dejavnosti | −13,18 mio. | −7,44 % |
Denar iz naložb | 1,34 mio. | 141,19 % |
Denar iz financiranja | 2,38 mio. | 1.067,65 % |
Neto sprememba denarnih sredstev | −9,46 mio. | 38,24 % |
Prost denarni tok | −12,34 mio. | −9,71 % |
Vizitka
Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator.
As of 2019, Axogen was the only commercially available allograft approved by the Food and Drug Administration for clinical use. Wikipedia
Datum ustanovitve
2002
Sedež organizacije
Spletno mesto
Zaposleni
452
